Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study

MARLBOROUGH, Mass., April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, mul... Devices, Neurology Boston Scientific, INTREPID study, deep brain stimulation, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

This study sought to determine whether there is a gender disparity in patients undergoing deep brain stimulation (DBS) surgery for Parkinson's disease (PD) at a single health system, and better understand the reasons for this discrepancy.Materials and MethodsWe analyzed data from the University of Miami DBS Database, which included 3251 PD patients, using chi ‐square, repeated measures ANOVA, andt tests to examine gender differences in the number of patients referred for surgery, reasons for referral, number receiving/not receiving surgery, reasons for not receiving surgery, and postsurgical outcomes.ResultsDuring the st...
Source: Neuromodulation: Technology at the Neural Interface - Category: Biotechnology Authors: Tags: Clinical Research Source Type: research
Authors: Shpiner DS, Bette S, Di Luca DG, Margolesky J Abstract INTRODUCTION: For patients with Parkinson's disease (PD), the treatment of motor and nonmotor fluctuations is tantamount to maintaining quality of life. Subcutaneous apomorphine has been the only commercially available rescue therapy for the treatment of OFF episodes. In December 2018, CVT-301 (Inbrija), an inhaled formulation of LD, was approved by the FDA for this indication. Areas covered: In this review the authors summarize the armamentarium available to address motor fluctuations in PD, including medications in development. The authors discuss the p...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Deep brain stimulation (DBS) has become the treatment of choice for advanced stages of Parkinson's disease, medically intractable essential tremor, and complicated segmental and generalized dystonia. In addition to accurate electrode placement in the target area, effective programming of DBS devices is considered the most important factor for the individual outcome after DBS. Programming of the implanted pulse generator (IPG) is the only modifiable factor once DBS leads have been implanted and it becomes even more relevant in cases in which the electrodes are located at the border of the intended target structure and when ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Authors: Niranjan A, Raju SS, Lunsford LD Abstract Tremor is the most prevalent movement disorder in adults. Patients who are refractory to medical management can explore surgical intervention. Deep-brain stimulation (DBS) and radiofrequency thalamotomy (RFT) are surgical procedures for intractable tremor that target the ventralis intermedius (VIM) nucleus to relieve contralateral tremor. For patients who are not candidates for surgical procedures, stereotactic radiosurgery (SRS) is a minimally invasive management option for tremor relief. SRS has been used for the elderly, those considered high surgical risk for o...
Source: Progress in Neurological Surgery - Category: Neurosurgery Tags: Prog Neurol Surg Source Type: research
Directional deep brain stimulation (dDBS) of the subthalamic nucleus for Parkinson ’s disease (PD) increases the therapeutic window. However, empirical programming of the neurostimulator becomes more complex given the increasing number of stimulation parameters. A better understanding of dDBS is needed to improve therapy and help guide postoperative programming.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
Abbott Laboratories and the National Institutes of Health have formed an alliance to evaluate applications that could help treat chronic pain and progressive movement disorders, like Parkinson’s disease. The collaboration is a part of NIH’s BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research. The agreement specifically calls for NIH to use the Abbott Park, IL-based company’s neuromodulation technologies for research related to these NIH initiatives to explore their application for chronic p...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news
This study aimed to produce such a screening tool by building a classifier that models specialist identification of suitable DAT candidates. To our knowledge, this is the first objective decision tool for managing DAT referral. Subjects were randomly assigned to either a construction set (n = 112, to train, develop, cross validate, and then evaluate the classifier’s performance) or to a test set (n = 60 to test the fully specified classifier), resulting in a sensitivity and specificity of 89% and 86.6%, respectively. The classifier’s performance was then assessed in PwP who underwent deep brain stimulat...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
We examined changes in personality domains in individuals with TRD following SCC-DBS, and personality measures as predictors of response to DBS.
Source: Biological Psychiatry - Category: Psychiatry Authors: Source Type: research
Dwarakanath SrinivasNeurology India 2019 67(2):395-396
Source: Neurology India - Category: Neurology Authors: Source Type: research
Conclusion: Presence of freezing of gait in the drug OFF state and executive dysfunction predict the occurrence of earlier dementia in PD patients who otherwise qualify for bilateral STN DBS.
Source: Neurology India - Category: Neurology Authors: Source Type: research
More News: Brain | Deep Brain Stimulation | Marketing | Neurology | Neuroscience | Parkinson's Disease | Pharmaceuticals | Study